NCT03742349
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy, Tyrosine-Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with symptomatic central nervous system (CNS) metastases that require therapy
https://ClinicalTrials.gov/show/NCT03742349